Annual Statements Open main menu

iCoreConnect Inc. - Quarter Report: 2019 March (Form 10-Q)

icct_10q.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

For the quarterly period ended March 31, 2019

 

Commission file number: 000-52765

 

iCoreConnect Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

Nevada

 

13-4182867

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

   13506 Summerport Village Pkwy #160, Windermere, FL 34786
(Address of principal executive offices) (Zip Code)

 

(888) 810-7706

(Registrant’s Telephone Number, Including Area Code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

¨

Accelerated filer

¨

Non-accelerated filer

¨

Smaller reporting company

x

(Do not check if a smaller reporting company)

Emerging growth company

¨

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

 

As of May 3, 2019, there were 56,647,902 shares of the registrant’s common stock issued and outstanding.

 

 
 
 
 

 

iCoreConnect Inc.

FORM 10-Q QUARTERLY REPORT

FOR THE QUARTER ENDED MARCH 31, 2019

 

Part I Financial Information

 

 

 

 

 

 

 

 

Item 1

Financial Statements (Unaudited)

 

 

 

Condensed Consolidated Balance Sheets as of March 31, 2019 and December 31, 2018 (Audited)

 

3

 

 

Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2019 and 2018

 

4

 

 

Condensed Consolidated Statements of Changes in Stockholders’ Deficit for the Three months ended March 31, 2019 and 2018

 

5

 

 

Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2019 and 2018

 

6

 

 

Notes to Consolidated Financial Statements

 

7

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

15

 

Item 3.

Quantitative and Qualitative Disclosures About Market Risks

 

18

 

 

Not applicable

 

 

 

Item 4.

Controls and Procedures

 

18

 

 

 

 

 

Part II Other Information

 

 

 

 

 

 

Item 1.

Legal Proceedings

 

19

 

Item 1A.

Risk Factors

 

19

 

 

Not Applicable

 

 

Item 2.

Unregistered Sales Of Equity Securities And Use Of Proceeds

 

19

 

Item 3.

Defaults Upon Senior Securities

 

19

 

 

Not Applicable

 

 

Items 4.

Mine Safety Disclosures

 

19

 

 

Not Applicable

 

 

Item 5.

Other Information

 

19

 

 

Not Applicable

 

 

 

Item 6.

Exhibits

 

20

 

 

 

 

 

Signatures

 

21

 


 

2

 
 

 

iCoreConnect Inc.

CONDENSED CONSOLIDATED BALANCE SHEETS

AS OF MARCH 31, 2019 (UNAUDITED) AND DECEMBER 31, 2018 (AUDITED)

 

 

 

 

 

 

 

 

March 31,

 

 

December 31,

 

 

 

2019

 

 

2018

 

ASSETS

 

 

 

 

 

 

Cash and cash equivalents

 

$ 139,000

 

 

$ 1,000

 

Accounts receivable, net of allowance for doubtful accounts

 

 

122,000

 

 

 

224,000

 

Right of use lease asset - operating

 

 

64,000

 

 

 

-

 

Prepaid expenses

 

 

26,000

 

 

 

9,000

 

Total current assets

 

 

351,000

 

 

 

234,000

 

 

 

 

 

 

 

 

 

 

Property and equipment, net

 

 

9,000

 

 

 

11,000

 

Right of use lease asset - operating

 

 

34,000

 

 

 

-

 

Software development costs, net

 

 

550,000

 

 

 

535,000

 

Acquired technology, net

 

 

518,000

 

 

 

539,000

 

Goodwill and intangible assets, net

 

 

411,000

 

 

 

416,000

 

Total long-term assets

 

 

1,522,000

 

 

 

1,501,000

 

 

 

 

 

 

 

 

 

 

TOTAL ASSETS

 

$ 1,873,000

 

 

$ 1,735,000

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS' DEFICIT

 

 

 

 

 

 

 

 

Accounts payable and accrued expenses

 

$ 650,000

 

 

$ 664,000

 

Line of credit

 

 

498,000

 

 

 

498,000

 

Operating lease liability

 

 

68,000

 

 

 

-

 

Current maturities of long-term debt

 

 

1,305,000

 

 

 

1,361,000

 

Total current liabilities

 

 

2,521,000

 

 

 

2,523,000

 

 

 

 

 

 

 

 

 

 

Long-term debt, net of current maturities

 

 

42,000

 

 

 

55,000

 

Operating lease liability

 

 

40,000

 

 

 

-

 

Deferred revenue

 

 

119,000

 

 

 

115,000

 

Total long-term liabilities

 

 

201,000

 

 

 

170,000

 

 

 

 

 

 

 

 

 

 

TOTAL LIABILITIES

 

 

2,722,000

 

 

 

2,693,000

 

 

 

 

 

 

 

 

 

 

STOCKHOLDERS' DEFICIT

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Preferred Stock, Undesignated par value $.001; 10,000,000 shares authorized; none issued or outstanding

 

 

-

 

 

 

-

 

Common stock par value $.001; 600,000,000 shares authorized; issued and outstanding: 53,472,238 as of March 31, 2019 and 50,864,131 as of December 31, 2018

 

 

53,000

 

 

 

51,000

 

Additional paid-in-capital

 

 

71,216,000

 

 

 

70,335,000

 

Accumulated deficit

 

 

(72,118,000 )

 

 

(71,344,000 )

TOTAL STOCKHOLDERS' DEFICIT

 

 

(849,000 )

 

 

(958,000 )

 

 

 

 

 

 

 

 

 

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT

 

$ 1,873,000

 

 

$ 1,735,000

 

 

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements

 

 
3
 
Table of Contents

 

iCoreConnect Inc.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE THREE MONTH PERIOD ENDED MARCH 31, 2019 AND 2018 (UNAUDITED)

 

 

 

Three Months

Ended

 

 

Three Months

Ended

 

 

 

March 31,

 

 

March 31,

 

 

 

2019

 

 

2018

 

Revenue

 

$ 280,000

 

 

$ 351,000

 

Cost of sales

 

 

88,000

 

 

 

106,000

 

Gross profit

 

 

192,000

 

 

 

245,000

 

 

 

 

 

 

 

 

 

 

Expenses

 

 

 

 

 

 

 

 

General and administrative

 

 

797,000

 

 

 

640,000

 

Depreciation and amortization

 

 

107,000

 

 

 

101,000

 

Total operating expenses

 

 

904,000

 

 

 

741,000

 

 

 

 

 

 

 

 

 

 

Loss from operations

 

 

(712,000 )

 

 

(496,000 )

 

 

 

 

 

 

 

 

 

Other expense

 

 

 

 

 

 

 

 

Interest expense

 

 

(49,000 )

 

 

(54,000 )

Other expense

 

 

-

 

 

 

(1,750,000 )

Total other expense

 

 

(49,000 )

 

 

(1,804,000 )

 

 

 

 

 

 

 

 

 

Net loss

 

$ (761,000 )

 

$ (2,300,000 )

 

 

 

 

 

 

 

 

 

Net loss per share available to common stockholders, basic and diluted

 

$ (0.01 )

 

$ (0.06 )

 

 

 

 

 

 

 

 

 

Weighted average number of shares, basic and diluted

 

 

52,210,810

 

 

 

38,485,689

 

 

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements

 

 
4
 
Table of Contents

  

iCoreConnect Inc.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES  IN STOCKHOLDERS' DEFICIT

FOR THE THREE MONTH PERIOD ENDED MARCH 31, 2019 AND 2018 (UNAUDITED)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

 

 

 

Total

 

 

 

Common stock

 

 

Paid In

 

 

Accumulated

 

 

Stockholders'

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Deficit

 

 

Deficit

 

Balances at January 1, 2018

 

 

34,318,198

 

 

$ 34,000

 

 

$ 64,856,000

 

 

$ (66,154,000 )

 

$ (1,264,000 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock issued for cash

 

 

1,867,000

 

 

 

2,000

 

 

 

543,000

 

 

 

-

 

 

 

545,000

 

Stock issued for employee services

 

 

3,400,000

 

 

 

3,000

 

 

 

1,697,000

 

 

 

-

 

 

 

1,700,000

 

Stock compensation expense

 

 

-

 

 

 

-

 

 

 

31,000

 

 

 

-

 

 

 

31,000

 

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(2,300,000 )

 

 

(2,300,000 )

Balances at March 31, 2018

 

 

39,585,198

 

 

$ 39,000

 

 

$ 67,127,000

 

 

$ (68,454,000 )

 

$ (1,288,000 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balances at January 1, 2019

 

 

50,864,131

 

 

$ 51,000

 

 

$ 70,335,000

 

 

$ (71,344,000 )

 

$ (958,000 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cumulative adjustment for the adoption of a new accounting pronouncement (Note 6)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(13,000 )

 

 

(13,000 )

Stock issued for cash and conversion of notes payable

 

 

2,395,607

 

 

 

2,000

 

 

 

673,000

 

 

 

-

 

 

 

675,000

 

Stock compensation expense

 

 

-

 

 

 

-

 

 

 

55,000

 

 

 

-

 

 

 

55,000

 

Vesting of restricted stock

 

 

212,500

 

 

 

-

 

 

 

153,000

 

 

 

-

 

 

 

153,000

 

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(761,000 )

 

 

(761,000 )

Balances at March 31, 2019

 

 

53,472,238

 

 

$ 53,000

 

 

$ 71,216,000

 

 

$ (72,118,000 )

 

$ (849,000 )

 

The accompanying notes are an integral part of these condensed consolidated financial statements

 

 
5
 
Table of Contents

  

iCoreConnect Inc.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE THREE MONTH PERIOD ENDED MARCH 31, 2019 AND 2018 (UNAUDITED)

 

 

 

Three months

ended

 

 

Three months

ended

 

 

 

March 31,

 

 

March 31,

 

 

 

2019

 

 

2018

 

CASH FLOWS FROM OPERATING ACTIVITIES:

 

 

 

 

 

 

Net loss

 

$ (761,000 )

 

$ (2,300,000 )

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Depreciation

 

 

1,000

 

 

 

1,000

 

Amortization

 

 

106,000

 

 

 

100,000

 

Shares issued for services

 

 

-

 

 

 

1,700,000

 

Change in allowance for doubtful accounts

 

 

-

 

 

 

2,000

 

Stock compensation expense

 

 

208,000

 

 

 

31,000

 

Decrease (increase) in:

 

 

 

 

 

 

 

 

Accounts receivable

 

 

102,000

 

 

 

(198,000 )

Prepaid expenses

 

 

(17,000 )

 

 

(5,000 )

Right of use asset, net of lease liability

 

 

(3,000 )

 

 

-

 

Accounts payable and accrued expenses

 

 

(14,000

)

 

 

164,000

 

Deferred revenue

 

 

4,000

 

 

 

24,000

 

NET CASH USED IN OPERATING ACTIVITIES

 

 

(374,000 )

 

 

(481,000 )

 

 

 

 

 

 

 

 

 

INVESTING ACTIVITIES

 

 

 

 

 

 

 

 

Amounts paid for capitalized software development

 

 

(94,000 )

 

 

(79,000 )

NET CASH USED IN INVESTING ACTIVITIES

 

 

(94,000 )

 

 

(79,000 )

 

 

 

 

 

 

 

 

 

FINANCING ACTIVITES

 

 

 

 

 

 

 

 

Increase in bank overdraft

 

 

-

 

 

 

10,000

 

Payments on long term debt

 

 

(49,000 )

 

 

(47,000 )

Proceeds from issuance of common stock

 

 

655,000

 

 

 

545,000

 

NET CASH PROVIDED BY FINANCING ACTIVITIES

 

 

606,000

 

 

 

508,000

 

 

 

 

 

 

 

 

 

 

NET INCREASE / (DECREASE) IN CASH

 

 

138,000

 

 

 

(52,000 )

CASH AND CASH EQUIVALENTS AT BEGINNING OF THE PERIOD

 

 

1,000

 

 

 

52,000

 

CASH AND CASH EQUIVALENTS AT END OF THE PERIOD

 

$ 139,000

 

 

$ -

 

 

 

 

 

 

 

 

 

 

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:

 

 

 

 

 

 

 

 

Cash paid during the period for interest

 

$ 36,000

 

 

$ 32,000

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements

 

 
6
 
Table of Contents

 

iCoreConnect Inc.

Notes to Condensed Consolidated Financial Statements

March 31, 2019.

(In thousands except share amounts)

 

1. NATURE OF OPERATIONS

 

iCoreConnect Inc., (“iCoreConnect” or the “Company”), a Nevada corporation, builds cloud-based healthcare software. The Company’s focus presently is on four different revenue streams: (1) Customized EHR platform technology that is specifically tailored to provide specialized medical practices with a technology that conforms to workflows of a practice’s particular medical discipline such as ophthalmology, dentistry, orthopedic and other specialties, (2) iCoreConnect’s cloud-based exchange, the iCoreExchange, which allows physicians, patients and other members of the healthcare community to exchange patient specific healthcare information securely via the internet, while maintaining compliance with all current Health Insurance Portability and Accountability Act (“HIPAA”) regulations, (3) International Statistical Classification of Diseases and Related Health Problems (ICD) coding software, a medical classification list by the World Health Organization (WHO), and (4) iCoreConnect has developed a Meaningful Use Consulting Division assisting both medical and dental healthcare providers becoming compliant to ultimately qualify for federal incentive funds under the Federal Meaningful Use Incentive Funds Program. iCoreConnect’s integrated software and service offering enables doctors to meet the regulatory burden associated with secure HIPAA compliant medical records transport with no change in healthcare delivery workflows.

 

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted pursuant to the Securities and Exchange Commission (“SEC”) rules and regulation. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto for the fiscal year ended December 31, 2018, which are included in the Company’s Annual Report filed on Form 10-K with the SEC on April 1, 2019. The accompanying condensed balance sheet as of December 31, 2018 has been derived from the audited financial statements at that date, but does not include all information and footnotes required by GAAP for complete financial statements.

 

The results of operations for the three month period ended March 31, 2019 are not necessarily indicative of results that may be expected for any other interim period or for the full fiscal year. Readers of this Quarterly Report are strongly encouraged to review the risk factors relating to the Company which are set forth in the Company’s Form 10-K filed with the SEC.

 

2. GOING CONCERN

  

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates continuity of operations, realization of assets, and liquidation of liabilities in the normal course of business. For the three month period ended March 31, 2019, the Company generated an operating loss of $761,000. In addition, the Company has an accumulated deficit, total stockholders’ deficit and net working capital deficit of $72,118,000, $849,000 and $2,170,000 at March 31, 2019, respectively. The Company’s activities were primarily financed through private placements of equity securities. The Company intends to raise additional capital through the issuance of debt or equity securities to fund its operations. The Company is reliant on future fundraising to finance operations in the near future. The financing may not be available on terms satisfactory to the Company, if at all. In light of these matters, there is substantial doubt that the Company will be able to continue as a going concern.

 

Currently, management intends to develop a vastly improved healthcare communications system and intends to develop alliances with strategic partners to generate revenues that will sustain the Company. While management believes in the viability of its strategy to increase revenues and in its ability to raise additional funds, there can be no assurances to that effect. Management’s ability to continue as a going concern is ultimately dependent upon its ability to continually increase the Company’s customer base and realize increased revenues from signed contracts. The financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

 

 
7
 
Table of Contents

 

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Accounting

 

The accompanying financial statements have been prepared on the accrual basis of accounting in accordance with GAAP. Significant accounting principles followed by the Company and the methods of applying those principles, which materially affect the determination of financial position, results of operations and cash flows are summarized below.

 

Cash and Cash Equivalents

 

The Company classifies highly liquid temporary investments with an original maturity of three months or less when purchased as cash equivalents. The Company maintains cash balances at various financial institutions. Balances at United States banks are insured by the Federal Deposit Insurance Corporation up to $250,000. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant risk for cash on deposit.

 

Accounts Receivable and Allowance for Doubtful Accounts

 

Accounts receivable are customer obligations due under normal trade terms. We maintain an allowance for doubtful accounts for estimated losses resulting from the potential inability of certain customers to make required future payments on amounts due us. Management determines the adequacy of this allowance by periodically evaluating the aging and past due nature of individual customer accounts receivable balances and considering the customer’s current financial situation as well as the existing industry economic conditions and other relevant factors that would be useful in assessing the risk of collectability. If the future financial condition of our customers were to deteriorate, resulting in their inability to make specific required payments, additions to the allowance for doubtful accounts may be required. In addition, if the financial condition of our customers improves and collections of amounts outstanding commence or are reasonably assured, then we may reverse previously established allowances for doubtful accounts. The Company has estimated and recorded an allowance for doubtful accounts of $12,000 both at March 31, 2019 and December 31, 2018.

 

Property, Equipment and Depreciation

 

Property, equipment, and leasehold improvements are recorded at their historical cost. Depreciation and amortization have been determined using the straight line method over the estimated useful lives of the assets which are computers and office equipment (3 years) and for office furniture and fixtures (7 years).

 

The cost of repairs and maintenance is charged to operations in the period incurred.

 

Software Development Costs and Acquired Software

 

The Company accounts for software development costs, including costs to develop software products or the software component of products to be sold to external users. In accordance with ASC 985-730, Computer Software Research and Development, research and planning phase costs are expensed as incurred and development phase costs including direct materials and services, payroll and benefits and interest costs are capitalized. We have determined that technological feasibility for our products to be marketed to external users was reached before the release of those products. As a result, the development costs and related acquisition costs after the establishment of technological feasibility were capitalized as incurred. Capitalized costs for software to be sold to external users and software acquired in a business combination are amortized based on current and projected future revenue for each product with an annual minimum equal to the straight-line amortization over three years.

 

Impairment of Long Lived Assets

 

Long lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount that the carrying amount of the asset exceeds the fair value of the asset.

 

 
8
 
Table of Contents

 

Goodwill

 

Goodwill acquired in a business combination is not amortized, but is tested for impairment annually or between annual tests when an impairment indicator exists. If an optional qualitative goodwill impairment assessment is not performed, we are required to determine the fair value of each reporting unit. If a reporting unit’s fair value is lower than its carrying value, we must determine the amount of implied goodwill that would be established if the reporting unit was hypothetically acquired on the impairment test date. If the carrying amount of a reporting unit’s goodwill exceeds the amount of implied goodwill, an impairment loss equal to the excess would be recorded. The recoverability of indefinite lived intangible assets is assessed by comparison of the carrying value of the asset to its estimated fair value. If we determine that the carrying value of the asset exceeds its estimated fair value, an impairment loss equal to the excess would be recorded.

 

Revenue Recognition

 

The Company has four primary sources of revenue:

 

 

· Electronic Health Records (EHR) licenses and rental services

 

· Encrypted Secure & HIPPA Compliant email services (“Encrypted Secure email”)

 

· ICD Coding Software

 

· Meaningful Use Consulting Services
 

Revenue from EHR software licensing arrangements include private cloud hosting services and post contract support provided to clients that have purchased a perpetual or specific term license to the EHR software solution and have contracted with the Company to host the software. These arrangements provide the client with a contractual right to take possession of the software at any time during the private cloud hosting period without significant penalty and it is feasible for the client to either use the software on its own equipment or to contract with an unrelated third party to host the software. The Company recognizes revenue from the sale of its EHR software license at the time the customer has access to use the software, with deferral of revenues associated with the cloud hosting and post contract support performance objectives, allocated based on relative fair value.

 

The Company defers revenue from the sale of its EHR software products associated with cloud hosting and post contract support performance objectives over the term of the license agreement. Cloud hosting performance objective revenues are deferred based on forecasted cloud storage costs, encrypted secure email performance objective revenues are deferred based on the forecasted sales price of those services to other customers of the Company and customer support performance objective revenues are deferred based on forecasted customer support costs based on Company experience.

 

Encrypted Secure email services are provided on a fee basis as software as a service (“SaaS”) arrangements and are recognized as revenue ratably over the contract terms beginning on the date our solutions are made available to the customer. The length of a period is monthly over which such customer has the right to use the Company’s SaaS Encrypted Secure email solution.

 

ICD coding services are provided on a fee basis as SaaS arrangements and are recognized as revenue ratably over the contract terms beginning on the date the Company’s solutions are made available to the customer. The length of a customer service period varies from multi-year annually renewed to monthly over which such customer has the right to use the Company’s ICD coding software solution.

 

Meaningful Use consulting service revenue is recognized in the period that the services are completed and the submission of the customer’s underlying application for Federal Meaningful Use Incentive Funds is received from the relevant taxing authority.

 

 
9
 
Table of Contents

   

Net Loss Per Share

 

Basic net loss per share is computed by dividing net loss by the weighted average number of shares of Common Stock outstanding for the period. Diluted net loss per share reflects the potential dilution of securities by adding other Common Stock equivalents, including stock options, shares issuable on exercise of warrants, convertible preferred stock and convertible notes in the weighted average number of common shares outstanding for a period, if dilutive. Common stock equivalents that are anti-dilutive were excluded from the computation of diluted earnings per share which consisted of all outstanding common stock options and warrants.

 

Stock-Based Compensation

 

The Company accounts for the granting of share purchase options using the fair value method whereby all awards are recorded at fair value on the date of the grant. Share based awards granted with a performance condition are measured based on the probable outcome of that performance condition during the requisite service period. Such an award with a performance condition is accrued if it is probable that a performance condition will be achieved. Compensation costs for stock-based payments that do not include performance conditions are recognized on a straight-line basis. The fair value of all share purchase options is expensed over their requisite service period with a corresponding increase to paid-in-capital. Upon exercise of share purchase options, the consideration paid by the option holder, together with the amount previously recognized in paid-in-capital, is recorded as an increase to common stock.

 

The fair value of restricted stock units issued are determined by the Company based on the estimated fair value the Company’s common stock. The Company estimates the fair value of each option award on the date of grant using a Black-Scholes option pricing model that uses the assumptions noted in the table below. The Company estimates the fair value of its common stock using the closing stock price of its common stock on the date of the agreement. The Company estimates the volatility of its common stock at the date of grant based on it’s historical stock prices. The Company determines the expected life based on historical experience with similar awards, giving consideration to the contractual terms, vesting schedules and post-vesting forfeitures. The Company uses the risk-free interest rate on the implied yield currently available on U.S. Treasury issues with an equivalent remaining term approximately equal to the expected life of the award. The Company has never paid any cash dividends on its common stock and does not anticipate paying any cash dividends in the foreseeable future.

 

Use of Estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.

 

Recently Issued Accounting Pronouncements

 

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which requires a lessee, in most leases, to initially recognize a lease liability for the obligation to make lease payments and a right-of-use asset for the right to use the underlying asset for the lease term. The guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those years. The guidance requires adoption using a modified retrospective transition approach with either 1) periods prior to the adoption date being recast or 2) a cumulative-effect adjustment recognized to the opening balance of retained earnings on the adoption date with prior periods not recast. The Company adopted this standard on January 1, 2019 using the cumulative-effect adjustment method and elected certain practical expedients allowed under the standard. As a result of the adoption, the Company increased assets and liabilities by approximately $112,000 and $125,000, respectively, and decreased retained earnings on January 1, 2019 by $13,000.

 

 
10
 
Table of Contents

 

In July 2017, the Financial Accounting Standards Board issued ASU No. 2017-11, “Accounting for Certain Financial Instruments with Down Round Features” (“Topic 480”). This update changes the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. ASU 2017-11 is effective for interim and annual periods beginning after December 15, 2018. The Company has evaluated the impact of the pronouncement on the financial statements and has determined that it will not have a significant impact on the financial statements.

 

In June 2018, the Financial Accounting Standards Board issued ASU No. 2018-07, “Compensation-Stock Compensation (“Topic 718”): Improvements to Nonemployee Share-Based Payment Accounting.” This update is intended to reduce cost and complexity and to improve financial reporting for share-based payments issued to nonemployees. ASU 2018-07 is effective for interim and annual periods beginning after December 15, 2018. The Company has implemented the guidance and determined the impact of the pronouncement on the financial statements did not have a significant impact on the financial statements.

 

The Company does not believe that any other issued, but not yet effective accounting standards, if currently adopted, will have a material effect on the Company’s consolidated financial position, results of operations and cash flows.

 

4. COMMON STOCK AND PREFERRED STOCK

  

Stock Issuances

 

During the three month period ended March 31, 2019, the Company issued 2,395,607 shares of common stock, for the conversion of a $20,000 note payable and cash proceeds totaling $655,000. The Company also issued 675,000 shares of restricted common stock as compensation to certain employees and directors for services performed, of which 212,500 shares have vested.

 

Stock Options

 

On February 21, 2019, our Board of Directors authorized the issuance of options to certain employees for 135,000 shares of Common stock, with an exercise price of $0.15, that vested upon issuance.

 

During the three month period ended March 31, 2019, no options to purchase shares of common stock granted to employees expired and no options were forfeited or exercised.

 

 
11
 
Table of Contents

 

A summary of option activity for the three month period ended March 31, 2019, is presented below:

  

Options Outstanding

 

 

 

 

 

Weighted

 

 

 

 

 

 

 

Weighted

 

 

Average

 

 

 

 

 

 

 

Average

 

 

Remaining

 

 

Aggregate

 

 

 

Number

 

 

Exercise

 

 

Contractual

 

 

Intrinsic

 

 

 

of Options

 

 

Price

 

 

Term in Years

 

 

Value

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Outstanding - January 1, 2019

 

 

1,356,157

 

 

$ 0.31

 

 

 

9.8

 

 

$ -

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

     Granted

 

 

135,000

 

 

$ 0.15

 

 

 

9.9

 

 

 

 

 

     Exercised

 

 

-

 

 

$ -

 

 

 

 

 

 

 

 

 

     Forfeited/expired

 

 

-

 

 

$ -

 

 

 

 

 

 

 

 

 

Balance outstanding - March 31, 2019

 

 

1,491,157

 

 

$ 0.29

 

 

 

9.6

 

 

$ -

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exercisable - March 31, 2019

 

 

624,490

 

 

$ 0.28

 

 

 

9.1

 

 

$ -

 

 

Nonvested Options

 

 

 

 

 

Weighted

 

 

 

 

 

 

 

 

Average

 

 

 

 

 

 

Weighted

 

 

Remaining

 

 

 

Number

 

 

Average grant date

 

 

Years

 

 

 

of Options

 

 

Fair Value

 

 

to vest

 

Nonvested - January 1, 2019

 

 

866,667

 

 

$ 0.13

 

 

 

1.6

 

 

 

 

 

 

 

 

 

 

 

 

 

 

     Granted

 

 

135,000

 

 

$ 0.25

 

 

 

 

 

     Vested

 

 

(135,000 )

 

$ 0.25

 

 

 

 

 

     Forfeited/expired

 

 

-

 

 

 

 

 

 

 

 

 

Nonvested - March 31, 2019

 

 

866,667

 

 

$ 0.13

 

 

 

1.4

 

    

 
12
 
Table of Contents

 

5. SOFTWARE DEVELOPMENT COSTS

 

The Company continued to develop its software products with significant features and enhancements during the three month period ended March 31, 2019 and has continued to capitalize development costs during that period. A summary of the capitalization and amortization of the software development costs is as follows:

 

 

 

March 31,

 

 

December 31,

 

 

 

2019

 

 

2018

 

 

 

 

 

 

 

 

Development costs

 

$ 1,607,000

 

 

$ 1,513,000

 

Acquired technology

 

 

630,000

 

 

 

630,000

 

Less accumulated amortization

 

 

(1,169,000 )

 

 

(1,069,000 )

 

 

$ 1,068,000

 

 

$ 1,074,000

 

 

6. COMMITMENTS AND CONTINGENCIES

 

LEASE COMMITMENTS

 

On November 15, 2017 the Company signed a three-year lease agreement for approximately 4,100 square feet of office space located in Winter Garden, Florida in which the Company has its headquarters. The lease provides for a one-year renewal term at the option of the Company. As of March 31, 2019, undiscounted future lease obligations for the office space are as follows:

 

Year Ended

 

Lease Amount

 

 

 

 

 

March 31, 2020

 

 

68,000

 

March 31, 2021

 

 

40,000

 

 

 

$ 108,000

 

 

On January 1, 2019, the Company adopted ASU 2016-02, Leases (Topic 842), which requires a lessee, in most leases, to initially recognize a lease liability for the obligation to make lease payments and a right-of-use asset for the right to use the underlying asset for the lease term. The Company adopted this standard using the cumulative-effect adjustment method and elected certain practical expedients allowed under the standard. As a result of the adoption, the Company increased assets and liabilities by approximately $112,000 and $125,000, respectively, and decreased retained earnings on January 1, 2019 by $13,000.

 

In arriving at the operating lease liabilities as of March 31, 2019, we applied the weighted-average incremental borrowing rate of 11.9% over a weighted-average remaining lease term of 1.6 years. Lease costs for the three months ended March 31, 2019 were $14,000 and cash paid for amounts included in the measurement of lease liabilities for the three months ended March 31, 2019 were $17,000. 

 

As of March 31, 2019, the following represents the difference between the remaining undiscounted lease commitments under non-cancelable leases and the lease liabilities:

 

Undiscounted minimum lease commitments

 

$ 108,000

 

Present value adjustment using incremental borrowing rate

 

 

(10,000 )

Lease liabilities

 

$ 98,000

 

 

 

13

 
Table of Contents

  

7. CONCENTRATION OF CREDIT RISK

 

The Company has historically provided financial terms to customers in accordance with what management views as industry norms. Financial terms range from immediate payment for access to the Company’s software products to several months for Meaningful Use consulting services. Management periodically and regularly reviews customer account activity in order to assess the adequacy of allowances for doubtful accounts, considering such factors as economic conditions and each customer’s payment history and creditworthiness. If the financial conditions of our customers were to deteriorate, or if they were otherwise unable to make payments in accordance with management’s expectations, we might have to increase our allowance for doubtful accounts, modify their financial terms and/or pursue alternative collection methods.

 

Revenue concentrations for the three months ended March 31, 2019 and 2018 and the accounts receivable concentrations at March 31, 2019 and December 31, 2018, expressed as a percentage of the Company’s revenue and accounts receivable, respectively, are as follows:

 

 

 

Net Sales for the three months ended

 

 

Net Sales for the three months ended

 

 

Accounts

receivable at

 

 

 

March 31,

 

 

March 31,

 

 

March 31,

 

 

December 31,

 

 

 

2019

 

 

2018

 

 

2019

 

 

2018

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Customer A

 

 

38 %

 

 

22 %

 

 

31 %

 

 

15 %

Customer B

 

 

19 %

 

 

0 %

 

 

45 %

 

 

0 %

Customer C

 

 

0 %

 

 

23 %

 

 

0 %

 

 

0 %

Customer D

 

 

0 %

 

 

14 %

 

 

0 %

 

 

0 %

Customer E

 

 

0 %

 

 

10 %

 

 

1 %

 

 

0 %

Customer F

 

 

0 %

 

 

0 %

 

 

0 %

 

 

42 %

Customer G

 

 

0 %

 

 

0 %

 

 

0 %

 

 

14 %

 

8. SUBSEQUENT EVENTS

 

Since March 31, 2019, the Company has issued 874,657 shares of common stock for cash proceeds totaling $241,000.

 

On April 30, 2019 iCoreConnect Inc., acquired substantially all of the assets of ClariCare Inc., an Indiana corporation, in exchange for $50,000 in cash and 2,301,007 shares of the Company’s Common Stock, subject to adjustment, and the assumption of certain specified liabilities and obligations of ClariCare Inc., all upon the terms and conditions set forth in an Asset Purchase Agreement dated as of April 30, 2019 (the “ClariCare Asset Purchase Agreement”).

 

 
14
 
Table of Contents

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Statements made in this Quarterly Report on Form 10-Q, including without limitation this Management’s Discussion and Analysis of Financial Condition and Operations, other than statements of historical information, are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be identified by such words as “may,” “will,” “expect,” “anticipate,” “believe,” “estimate” and “continue” or similar words. We believe it is important to communicate our future expectations to investors. However, these forward-looking statements involve many risks and uncertainties, including the risk factors disclosed under the heading “Risk Factors” included in the Company’s Form 10-K filed with the Securities and Exchange Commission (“SEC”) on April 1, 2019. Our actual results could differ materially from those indicated in such forward-looking statements as a result of certain factors. We are under no duty to update any of the forward-looking statements after the date of this Report on Form 10-Q to conform these statements to actual results, other than to comply with the federal securities laws.

 

About the Company

 

iCoreConnect Inc., a Nevada corporation (the “Company”), creates communication and practice management cloud-based healthcare software that allows our customers to share information at the highest level of security. We are a national provider of secure communications for high-compliance industries including healthcare and potentially for the financial and legal industries. Our software allows organizations and individuals to easily exchange information utilizing 2048-bit encryption in full compliance of current federal laws.

 

Financing

 

We are currently funding our business capital requirements through revenues from product sales and consulting services, sales of our common stock and debt arrangements. While we intend to seek additional funding, if revenue increases to a point where we are able to sustain ourselves and increase our budget to match our growth needs, we may significantly reduce the amount of investment capital we seek. The amount of funds raised and revenue generated, if any, will determine how aggressively we can grow and what additional projects we will be able to undertake. No assurance can be given that we will be able to raise additional capital when needed or at all, or that such capital, if available, will be on terms acceptable to us. If we are unable to, or do not raise additional capital in the near future or if our revenue does not begin to grow as we expect, we will have to curtail our spending and downsize our operations.

 

Critical Accounting Policies and Estimates

 

Our discussion and analysis of financial condition and results of operations are based upon the financial statements, which have been prepared in accordance with generally accepted accounting principles as recognized in the United States of America. The preparation of these financial statements requires that we make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses, and disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that management believes to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.

  

Revenue Recognition

 

We have 4 primary sources of revenue:

 

 

· Electronic Health Records (EHR) licenses

 

 

 

 

· Encrypted & HIPAA Compliant Secure email

 

 

 

 

· ICD Coding Software

 

 

 

 

· Meaningful Use Consulting

 

 

 

 

· Revenue from EHR software licensing arrangements include private cloud hosting services provided to clients that have purchased a perpetual or specific term license to our EHR software solution and are contracted with us to host the software. These arrangements provide the client with a contractual right to take possession of the software at any time during the private cloud hosting period without significant penalty and it is feasible for the client to either use the software on its own equipment or to contract with an unrelated third party to host the software. Private cloud hosting services are not deemed to be essential to the functionality of the software. The Company recognizes revenue from the sale of its EHR software license at the time the customer has access to use the software, with deferral of revenues associated with the cloud hosting and post contract support performance objectives, allocated based on relative fair value.

 

 
15
 
Table of Contents

 

 

 

The Company defers revenue from the sale of its EHR software products associated with cloud hosting and post contract support performance objectives over the term of the license agreement. Cloud hosting performance objective revenues are deferred based on forecasted cloud storage costs, encrypted secure email performance objective revenues are deferred based on the forecasted sales price of those services to other customers of the Company and customer support performance objective revenues are deferred based on forecasted customer support costs based on Company experience.

 

 

 

 

· Encrypted Secure email services are provided on a fee basis as software as a service (“SaaS”) arrangements and are recognized as revenue ratably over the contract terms beginning on the date our solutions are made available to clients. The length of a client service period is monthly over which such client has the right to use our SaaS Encrypted Secure email solution.

 

 

 

 

· ICD Coding Software provides the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD), a medical classification list by the World Health Organization (WHO). It contains codes for diseases, signs and symptoms, abnormal findings, complaints, social circumstances, and external causes of injury or diseases. ICD coding services are provided on a fee basis as software as a service (“SaaS”) arrangements and are recognized as revenue ratably over the contract terms beginning on the date our solutions are made available to clients. The length of a client service period varies from multi-year annually renewed to monthly over which such client has the right to use our ICD coding software solution.

 

 

 

 

· Meaningful Use Consulting service revenues are recognized for consulting services provided to physician and dental practices at the successful submission of the Meaningful Use application to the appropriate governmental agency. Revenue is recognized at the contracted percentage of the Meaningful Use incentive program on each annual government award received by the client and is required to be paid when payment is received by the physician or dental practice.

 

Software Development Capitalization and Amortization

 

We account for software development costs, including costs to develop software products or the software component of products to be marketed to external users.

 

In accordance with ASC 985-730, Computer Software Research and Development, research and planning phase costs should be expensed as incurred and development phase costs including direct materials and services, payroll and benefits and interest costs may be capitalized.

 

We have determined that technological feasibility for our products to be marketed to external users was reached before the release of those products. As a result, the development costs and related acquisition costs after the establishment of technological feasibility were capitalized as incurred. Capitalized costs for software to be marketed to external users are amortized based on current and projected future revenue for each product with an annual minimum equal to the straight-line amortization over three years.

 

Stock Based Compensation

 

The Company estimates the fair value of each option award on the date of grant generally using a Black-Scholes option pricing model that uses the following assumptions. The Company estimates the fair value of its shares of restricted common stock using the closing stock price of its common stock on the date of the award. The Company estimates the volatility of its common stock at the date of grant based on its historical stock prices. The Company determines the expected life based on historical experience with similar awards, giving consideration to the contractual terms, vesting schedules and post-vesting forfeitures. The Company uses the risk-free interest rate on the implied yield currently available on U.S. Treasury issues with an equivalent remaining term approximately equal to the expected life of the award. The Company has never paid cash dividends on its common stock and does not anticipate paying any cash dividends in the foreseeable future.

 

Results of Operations

 

Overview. The following table sets forth our selected financial data for the periods indicated below and the percentage dollar increase (decrease) of such items from period to period:

  

 

 

Three Months

 

 

Three Months

 

 

 

 

 

 

Ended

 

 

Ended

 

 

 Percentage

 

 

 

March 31,

 

 

March 31,

 

 

 Increase /

 

 

 

2019

 

 

2018

 

 

 (Decrease)

 

Revenue

 

$ 280,000

 

 

$ 351,000

 

 

 

-20

%

Cost of sales

 

 

88,000

 

 

 

106,000

 

 

 

-17

%

General & administrative expense

 

 

797,000

 

 

 

640,000

 

 

 

25 %

Depreciation & amortization

 

 

107,000

 

 

 

101,000

 

 

 

6 %

Loss from operations

 

 

(712,000 )

 

 

(496,000 )

 

 

44 %

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense

 

 

(49,000 )

 

 

(54,000 )

 

 

-9

%

Other Expense

 

 

-

 

 

 

(1,750,000 )

 

 

-100

%

Net loss

 

$ (761,000 )

 

$ (2,300,000 )

 

 

-67

%

   

The accompanying “Management’s Discussion and Analysis of Financial Condition and Results of Operations” provides a comparison of the amounts listed above.

 

 
16
 
Table of Contents

 

Three Month Period Ended March 31, 2019 (“1Q 2019”) Compared to Three Month Period Ended March 31, 2018 (“1Q 2018”)

 

Revenues. Net revenues of $280,000 for the 1Q 2019 period decreased $71,000 or 20% compared to $351,000 for the 1Q 2018 period. The decrease was primarily due to a 57% decrease in EHR software revenues, somewhat offset by a 39% increase in iCoreCodeGenius revenues compared to the 1Q 2018 period.

 

Cost of sales. Cost of sales of $88,000 for the 1Q 2019 period decreased 17% compared to the 1Q 2018 period cost of sales of $106,000. The primary reason for the decrease was due to a decrease in software implementation wages and related expenses compared to the 1Q 2018 period.

 

General and administrative expenses. General and administrative expenses of $797,000 for the 1Q 2019 period increased $157,000 or 25% compared to $640,000 for the 1Q 2018 period. The increase was primarily due to a 31% increase in employee salaries and stock compensation expense and a 26% increase in professional and legal fees somewhat offset by a 91% decrease in advertising expenses compared to the 1Q 2018 period.

 

Depreciation and amortization expenses. Depreciation and amortization expenses of $107,000 for the 1Q 2019 period were $6,000 higher than the $101,000 for the 1Q 2018 period. The increase is primarily due to amortization of software development assets.

 

Interest Expense. Interest expense in the 1Q 2019 period of $49,000 was a decrease of $5,000 or 9% compared to $54,000 in the 1Q 2018 period. The decrease is due to a decrease of long term debt in 1Q 2019 compared to 1Q 2018.

 

Other Expense. Other expense in the 1Q 2018 period was related to the acquisition of Electro-Fish Media, Inc. in January 2018.

 

BALANCE SHEET TABLE

 

The following table sets forth our selected financial data for the periods indicated below and the percentage dollar increase (decrease) of such items from period to period:

 

 

 

 

 

 

 

Percentage

 

 

 

March 31,

 

 

December 31,

 

 

Increase /

 

Balance Sheet Data

 

2019

 

 

2018

 

 

(Decrease)

 

Current assets

 

$ 351,000

 

 

$ 234,000

 

 

 

50 %

Current liabilities

 

 

2,521,000

 

 

 

2,523,000

 

 

 

0 %

Working capital (deficit)

 

 

(2,170,000 )

 

 

(2,289,000 )

 

 

-5

%

 

 

 

 

 

 

 

 

 

 

 

 

 

Deferred revenue

 

 

119,000

 

 

 

115,000

 

 

 

3 %

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding

 

 

52,210,810

 

 

 

44,622,040

 

 

 

 

 

 

The primary factors that influence our liquidity include, but are not limited to, the amount and timing of our revenues, cash collections from our clients, capital expenditures and investments in research and development efforts. The change in our cash and cash equivalents balance is reflective of the following: We generated positive cash flow from financing activities during the three month period ending March 31, 2019 and cash from financing activities was used to fund operating activities, including investing in software product development and general and administrative expenses.

 

 
17
 
Table of Contents

 

The following table summarizes the impact of operating, investing and financing activities on our cash flows for the three month periods ended March 31, 2019 and March 31, 2018 related to our operations:

 

 

 

Three Months Ended

 

 

Three Months Ended

 

 

 

March 31,

 

 

March 31,

 

 

 

2019

 

 

2018

 

 

 

 

 

 

 

 

Net cash used in operating activities

 

$ (374,000 )

 

$ (481,000 )

 

 

 

 

 

 

 

 

 

Net cash used in investing activities

 

 

(94,000 )

 

 

(79,000 )

 

 

 

 

 

 

 

 

 

Net cash provided by financing activities

 

 

606,000

 

 

 

508,000

 

 

 

 

 

 

 

 

 

 

 Net Increase / (Decrease) in cash

 

 

138,000

 

 

 

(52,000 )

 

 

 

 

 

 

 

 

 

 Cash and cash equivalents at beginning of the period

 

 

1,000

 

 

 

52,000

 

 

 

 

 

 

 

 

 

 

 Cash and cash equivalents at the end of the period

 

$ 139,000

 

 

$ -

 

 

Operating Activities: Net cash used by operating activities for the three month period ending March 31, 2019 of $374,000 was $107,000 less than the $481,000 for the three month period ended March 31, 2018. The decrease in cash utilized by operating activities compared to the three month period March 31, 2018 was attributable to a $20,000 decrease in net loss and non cash adjustments to net loss and a $87,000 decrease in the cash impact of changes in operating assets and liabilities.

 

Investing Activities: Net cash used by investing activities for the three month period ending March 31, 2019 of $94,000 was primarily due to software development costs compared to $79,000 for the March 31, 2018 period. Future spending on investing activities is expected to be funded by additional issuance of common stock.

  

Financing Activities: Net cash provided by financing activities was $606,000 for the three month period ending March 31, 2019, due to the issuance of additional common stock compared to financing activities of $508,000 the three months ended March 31, 2018. Future cash provided by financing activities to meet capital spending requirements is expected to be funded by the issuance of additional shares of common stock.

 

Credit Facilities

 

Effective October 29, 2013, the Company entered into a revolving line of credit agreement in the amount of $250,000, which was increased to $500,000 on March 12, 2014 and $750,000 on September 9, 2014. The line of credit was reduced to $500,000 in May 2016 leaving $2,000 of availability as of March 31, 2019. The line of credit is collateralized by all assets of the Company and a guarantee by a stockholder of the Company. The line carries interest at the Wall Street Journal Prime rate + 1.0% with a floor rate of 6.5% (6.5% at March 31, 2019). Interest is payable monthly with all outstanding principal and interest due on July 15, 2019.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS

 

Not applicable.

 

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated our disclosure controls and procedures. Based on such evaluation, and after considering the controls implemented to mitigate the significant deficiency related to insufficient accounting personnel discussed in our SEC filing on Form 10-K dated December 31, 2018, our Chief Executive Officer and Chief Financial Officer have concluded that, as of March 31, 2019, our disclosure controls and procedures were effective in ensuring that information relating to the Company required to be disclosed in the reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, including ensuring that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

 

Changes to Internal Control Over Financial Reporting

 

We have not identified any change in our internal control over financial reporting during our most recently completed fiscal quarter that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

 
18
 
Table of Contents

 

PART II - OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

The Company from time to time, may be party to various litigation, claims and disputes, arising in the ordinary course of business. While the ultimate effect of such actions cannot be predicted with certainty, we believe the outcome of these matters will not have a material adverse effect on our financial condition or results of operations.

 

ITEM 1A. RISK FACTORS

 

Not applicable.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

None

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

Not applicable.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5. OTHER INFORMATION

 

Not applicable.

 

 
19
 
Table of Contents

 

ITEM 6. EXHIBITS

 

31.1*

 

Certification by the Principal Executive Officer of Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a)).

 

 

 

31.2*

 

Certification by the Principal Financial Officer of Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a)).

 

 

 

32.1*

 

Certification by the Principal Executive Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

32.2*

 

Certification by the Principal Financial Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 
20
 
Table of Contents

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

iCoreConnect, Inc. (Registrant)

       
Date: May 10, 2019 By: /s/ Robert McDermott

 

 

Robert McDermott  
    Chief Executive Officer  
    (Principal Executive Officer)  

 

 

 

 

Date: May 10, 2019

By:

/s/ Scott Malmanger

 

 

 

Scott Malmanger

 

 

 

Chief Financial Officer

 

 

 

(Principal Accounting Officer)

 

 

 
21